NUR 635 ADVANCED PHARMACOLOGY FINAL EXAMINATION BANK 2026/2027
COMPREHENSIVE REVIEW WITH VERIFIED ANSWERS AND RATIONALES
TYLER/SARHAN CURRICULUM ALIGNED | UPDATED EVIDENCE-BASED PRACTICE
SECTION A: PHARMACOKINETICS AND PHARMACODYNAMICS
1. A patient with severe hepatic impairment requires a medication that undergoes
extensive first-pass metabolism. Which adjustment is most appropriate?
A. Increase the dose to achieve therapeutic effect
B. Administer the medication via intravenous route
C. Decrease the dose by 50% and monitor closely
D. Use a pro-drug formulation to enhance absorption
Answer: B. Administer the medication via intravenous route
Rationale: First-pass metabolism occurs in the liver; bypassing this through IV
administration avoids hepatic extraction, allowing therapeutic drug levels without dose
adjustment.
2. A 72-year-old patient with renal impairment (CrCl 25 mL/min) is prescribed digoxin.
What is the most critical pharmacokinetic consideration?
A. Decreased protein binding requiring higher doses
B. Reduced renal clearance leading to drug accumulation
C. Increased volume of distribution requiring loading dose
D. Enhanced hepatic metabolism reducing drug efficacy
Answer: B. Reduced renal clearance leading to drug accumulation
Rationale: Digoxin is primarily eliminated renally; decreased GFR leads to accumulation
and increased risk of toxicity, requiring dose reduction.
3. Which characteristic of a drug would result in the longest half-life?
A. High renal clearance and small volume of distribution
,B. Low hepatic clearance and large volume of distribution
C. High protein binding and rapid metabolism
D. Low lipid solubility and rapid renal excretion
Answer: B. Low hepatic clearance and large volume of distribution
Rationale: Half-life is directly proportional to volume of distribution and inversely
proportional to clearance; large Vd with low clearance prolongs elimination.
4. A patient develops tolerance to morphine after chronic use. This phenomenon is
best explained by which pharmacodynamic mechanism?
A. Decreased receptor number (downregulation)
B. Increased drug metabolism via CYP450 induction
C. Enhanced renal excretion of the drug
D. Increased plasma protein binding
Answer: A. Decreased receptor number (downregulation)
Rationale: Chronic opioid exposure causes receptor internalization and downregulation,
reducing response to the same drug dose.
5. When administering two drugs that are highly protein-bound, which effect is most
likely to occur?
A. Decreased free drug concentration of both drugs
B. Increased risk of toxicity from displacement
C. Enhanced drug metabolism in the liver
D. Reduced drug distribution to target tissues
Answer: B. Increased risk of toxicity from displacement
Rationale: Competition for protein binding sites increases free (active) drug concentration,
potentially leading to toxicity in the displaced drug.
6. A patient with a history of peptic ulcer disease requires NSAID therapy. Which COX
inhibitor selectivity would provide the safest profile?
A. Non-selective COX-1/COX-2 inhibitor
B. Selective COX-2 inhibitor
C. COX-1 preferential inhibitor
D. Non-selective with buffering agent
Answer: B. Selective COX-2 inhibitor
Rationale: COX-2 selective inhibitors spare COX-1 mediated gastric mucosal protection,
reducing GI ulcer risk.
7. For a drug with a therapeutic index of 2, which statement is most accurate regarding
its safety profile?
A. The drug has a wide safety margin and can be dosed liberally
,B. The drug requires careful dose titration and monitoring
C. The drug is completely safe at any therapeutic dose
D. The drug cannot achieve toxic levels in clinical practice
Answer: B. The drug requires careful dose titration and monitoring
Rationale: A narrow therapeutic index (TI < 3) indicates a small margin between therapeutic
and toxic doses, necessitating close monitoring.
8. The administration of grapefruit juice with certain medications primarily affects
which pharmacokinetic process?
A. Renal tubular secretion
B. First-pass metabolism via CYP3A4 inhibition
C. Gastrointestinal absorption
D. Protein binding displacement
Answer: B. First-pass metabolism via CYP3A4 inhibition
Rationale: Grapefruit juice inhibits intestinal CYP3A4, increasing bioavailability of drugs
subject to first-pass metabolism.
9. A patient receiving warfarin is prescribed amiodarone. What is the primary
mechanism of this significant drug interaction?
A. Displacement of warfarin from plasma proteins
B. Inhibition of CYP2C9-mediated warfarin metabolism
C. Enhanced vitamin K absorption
D. Competition for renal excretion
Answer: B. Inhibition of CYP2C9-mediated warfarin metabolism
Rationale: Amiodarone inhibits CYP2C9 and CYP1A2, reducing warfarin clearance and
potentiating its anticoagulant effect.
10. Which statement best describes the concept of pharmacogenomics in drug
therapy?
A. The study of drug effects on genomic expression
B. The influence of genetic variations on drug response
C. The use of drugs to modify genetic material
D. The study of drug interactions at the genomic level
Answer: B. The influence of genetic variations on drug response
Rationale: Pharmacogenomics examines how genetic variations affect drug metabolism,
efficacy, and toxicity.
11. A patient with heart failure is receiving digoxin and furosemide. Which electrolyte
disturbance increases the risk of digoxin toxicity?
A. Hyperkalemia
, B. Hyponatremia
C. Hypokalemia
D. Hypercalcemia
Answer: C. Hypokalemia
Rationale: Hypokalemia increases myocardial sensitivity to digoxin, potentiating its toxicity
and arrhythmogenic effects.
12. When considering drug distribution, which factor is most important for drugs that
cross the blood-brain barrier?
A. Molecular weight > 500 Daltons
B. High water solubility
C. High lipid solubility
D. High degree of ionization
Answer: C. High lipid solubility
Rationale: The blood-brain barrier is lipid-rich; lipid-soluble drugs cross more readily due to
passive diffusion through cell membranes.
13. A patient with chronic kidney disease is prescribed a medication that is
predominantly excreted by the kidneys. How should the prescriber adjust the
maintenance dose?
A. Use the same dose but extend the dosing interval
B. Increase the dose to compensate for reduced clearance
C. Use a loading dose with same maintenance schedule
D. No adjustment is required for renal impairment
Answer: A. Use the same dose but extend the dosing interval
Rationale: Extending the dosing interval maintains therapeutic levels while preventing
accumulation in renal impairment.
14. The most accurate definition of a partial agonist is:
A. A drug that fully activates receptors to produce maximum effect
B. A drug that binds to receptors and produces submaximal effect
C. A drug that binds to receptors but produces no effect
D. A drug that blocks receptor activation by other agonists
Answer: B. A drug that binds to receptors and produces submaximal effect
Rationale: Partial agonists have intrinsic activity between 0 and 1, producing less than
maximum response even at full receptor occupancy.
15. Which phase of drug metabolism typically involves conjugation reactions?
A. Phase I oxidation reactions
B. Phase II synthetic reactions
COMPREHENSIVE REVIEW WITH VERIFIED ANSWERS AND RATIONALES
TYLER/SARHAN CURRICULUM ALIGNED | UPDATED EVIDENCE-BASED PRACTICE
SECTION A: PHARMACOKINETICS AND PHARMACODYNAMICS
1. A patient with severe hepatic impairment requires a medication that undergoes
extensive first-pass metabolism. Which adjustment is most appropriate?
A. Increase the dose to achieve therapeutic effect
B. Administer the medication via intravenous route
C. Decrease the dose by 50% and monitor closely
D. Use a pro-drug formulation to enhance absorption
Answer: B. Administer the medication via intravenous route
Rationale: First-pass metabolism occurs in the liver; bypassing this through IV
administration avoids hepatic extraction, allowing therapeutic drug levels without dose
adjustment.
2. A 72-year-old patient with renal impairment (CrCl 25 mL/min) is prescribed digoxin.
What is the most critical pharmacokinetic consideration?
A. Decreased protein binding requiring higher doses
B. Reduced renal clearance leading to drug accumulation
C. Increased volume of distribution requiring loading dose
D. Enhanced hepatic metabolism reducing drug efficacy
Answer: B. Reduced renal clearance leading to drug accumulation
Rationale: Digoxin is primarily eliminated renally; decreased GFR leads to accumulation
and increased risk of toxicity, requiring dose reduction.
3. Which characteristic of a drug would result in the longest half-life?
A. High renal clearance and small volume of distribution
,B. Low hepatic clearance and large volume of distribution
C. High protein binding and rapid metabolism
D. Low lipid solubility and rapid renal excretion
Answer: B. Low hepatic clearance and large volume of distribution
Rationale: Half-life is directly proportional to volume of distribution and inversely
proportional to clearance; large Vd with low clearance prolongs elimination.
4. A patient develops tolerance to morphine after chronic use. This phenomenon is
best explained by which pharmacodynamic mechanism?
A. Decreased receptor number (downregulation)
B. Increased drug metabolism via CYP450 induction
C. Enhanced renal excretion of the drug
D. Increased plasma protein binding
Answer: A. Decreased receptor number (downregulation)
Rationale: Chronic opioid exposure causes receptor internalization and downregulation,
reducing response to the same drug dose.
5. When administering two drugs that are highly protein-bound, which effect is most
likely to occur?
A. Decreased free drug concentration of both drugs
B. Increased risk of toxicity from displacement
C. Enhanced drug metabolism in the liver
D. Reduced drug distribution to target tissues
Answer: B. Increased risk of toxicity from displacement
Rationale: Competition for protein binding sites increases free (active) drug concentration,
potentially leading to toxicity in the displaced drug.
6. A patient with a history of peptic ulcer disease requires NSAID therapy. Which COX
inhibitor selectivity would provide the safest profile?
A. Non-selective COX-1/COX-2 inhibitor
B. Selective COX-2 inhibitor
C. COX-1 preferential inhibitor
D. Non-selective with buffering agent
Answer: B. Selective COX-2 inhibitor
Rationale: COX-2 selective inhibitors spare COX-1 mediated gastric mucosal protection,
reducing GI ulcer risk.
7. For a drug with a therapeutic index of 2, which statement is most accurate regarding
its safety profile?
A. The drug has a wide safety margin and can be dosed liberally
,B. The drug requires careful dose titration and monitoring
C. The drug is completely safe at any therapeutic dose
D. The drug cannot achieve toxic levels in clinical practice
Answer: B. The drug requires careful dose titration and monitoring
Rationale: A narrow therapeutic index (TI < 3) indicates a small margin between therapeutic
and toxic doses, necessitating close monitoring.
8. The administration of grapefruit juice with certain medications primarily affects
which pharmacokinetic process?
A. Renal tubular secretion
B. First-pass metabolism via CYP3A4 inhibition
C. Gastrointestinal absorption
D. Protein binding displacement
Answer: B. First-pass metabolism via CYP3A4 inhibition
Rationale: Grapefruit juice inhibits intestinal CYP3A4, increasing bioavailability of drugs
subject to first-pass metabolism.
9. A patient receiving warfarin is prescribed amiodarone. What is the primary
mechanism of this significant drug interaction?
A. Displacement of warfarin from plasma proteins
B. Inhibition of CYP2C9-mediated warfarin metabolism
C. Enhanced vitamin K absorption
D. Competition for renal excretion
Answer: B. Inhibition of CYP2C9-mediated warfarin metabolism
Rationale: Amiodarone inhibits CYP2C9 and CYP1A2, reducing warfarin clearance and
potentiating its anticoagulant effect.
10. Which statement best describes the concept of pharmacogenomics in drug
therapy?
A. The study of drug effects on genomic expression
B. The influence of genetic variations on drug response
C. The use of drugs to modify genetic material
D. The study of drug interactions at the genomic level
Answer: B. The influence of genetic variations on drug response
Rationale: Pharmacogenomics examines how genetic variations affect drug metabolism,
efficacy, and toxicity.
11. A patient with heart failure is receiving digoxin and furosemide. Which electrolyte
disturbance increases the risk of digoxin toxicity?
A. Hyperkalemia
, B. Hyponatremia
C. Hypokalemia
D. Hypercalcemia
Answer: C. Hypokalemia
Rationale: Hypokalemia increases myocardial sensitivity to digoxin, potentiating its toxicity
and arrhythmogenic effects.
12. When considering drug distribution, which factor is most important for drugs that
cross the blood-brain barrier?
A. Molecular weight > 500 Daltons
B. High water solubility
C. High lipid solubility
D. High degree of ionization
Answer: C. High lipid solubility
Rationale: The blood-brain barrier is lipid-rich; lipid-soluble drugs cross more readily due to
passive diffusion through cell membranes.
13. A patient with chronic kidney disease is prescribed a medication that is
predominantly excreted by the kidneys. How should the prescriber adjust the
maintenance dose?
A. Use the same dose but extend the dosing interval
B. Increase the dose to compensate for reduced clearance
C. Use a loading dose with same maintenance schedule
D. No adjustment is required for renal impairment
Answer: A. Use the same dose but extend the dosing interval
Rationale: Extending the dosing interval maintains therapeutic levels while preventing
accumulation in renal impairment.
14. The most accurate definition of a partial agonist is:
A. A drug that fully activates receptors to produce maximum effect
B. A drug that binds to receptors and produces submaximal effect
C. A drug that binds to receptors but produces no effect
D. A drug that blocks receptor activation by other agonists
Answer: B. A drug that binds to receptors and produces submaximal effect
Rationale: Partial agonists have intrinsic activity between 0 and 1, producing less than
maximum response even at full receptor occupancy.
15. Which phase of drug metabolism typically involves conjugation reactions?
A. Phase I oxidation reactions
B. Phase II synthetic reactions
